Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer: A Clinicopathologic Study
| Autor: | M. Orlowska-Volk, Schuele Roland Dr, Annettee Hasenburg, Judith Müller, Boris Gabriel, Axel zur Hausen, Dagmar-C Fischer |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
medicine.medical_specialty Pathology Antineoplastic Agents Hormonal Survival LIM-Homeodomain Proteins Muscle Proteins Breast Neoplasms 03 medical and health sciences 0302 clinical medicine Breast cancer Predictive Value of Tests Transcription (biology) medicine Humans Aged LIM domain Aged 80 and over Homeodomain Proteins 030219 obstetrics & reproductive medicine business.industry Gene Expression Profiling Obstetrics and Gynecology Cancer Middle Aged Prognosis medicine.disease Immunohistochemistry FHL2 Androgen receptor Tamoxifen Receptors Androgen Cancer research Female Histopathology business 030217 neurology & neurosurgery Transcription Factors |
| Zdroj: | Journal of the Society for Gynecologic Investigation. 13:69-75 |
| ISSN: | 1071-5576 |
| Popis: | Although the Four and a Half LIM domain protein 2 (FHL2) has been suggested to play an important role in tumor development, this has not been investigated in breast cancer.Paraffin-embedded tissues from patients (n = 85) with primary breast cancer were submitted to immunohistochemical investigation of FHL2 expression and subsequent correlation with clinicopathologic parameters and patient survival.The expression of FHL2 was confined to the cytoplasm of the tumor cells. Forty (47%) of 85 samples showed weak expression of FHL2, whereas high expression was found in 45 tumors (53%). A statistically significant positive correlation was observed between FHL2 and androgen receptor expression (P = .029). Patients with tumors expressing low amounts of FHL2 were characterized by a significantly better survival compared to those with high intratumoral FHL2 expression (P = .0215, log-rank test). The additional stratification according to adjuvant tamoxifen treatment revealed a significantly improved survival rate for patients receiving tamoxifen and being diagnosed with a tumor expressing high amounts of FHL2. This might indicate that tamoxifen is at least partially capable of reversing the negative prognostic impact of high FHL2 expression. Multivariate Cox regression analysis revealed FHL2 expression as a significant independent predictor of survival.The specific expression in tumor tissue points to an important functional role of FHL2 in human breast cancer. Our survival data indicate that the expression of FHL2 in primary breast cancer is a potentially relevant prognostic factor. Further studies are warranted to elucidate whether analysis of FHL2 expression is suitable to predict response to antihormonal treatment with tamoxifen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink